AC Immune (NASDAQ:ACIU) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.
Separately, Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th.
Shares of AC Immune (ACIU) traded up $0.09 on Friday, reaching $13.52. 17,474 shares of the company’s stock traded hands, compared to its average volume of 45,361. AC Immune has a 52 week low of $6.03 and a 52 week high of $13.91.
Several large investors have recently bought and sold shares of the company. Wells Fargo & Company MN acquired a new stake in shares of AC Immune during the third quarter worth $111,000. Janney Montgomery Scott LLC acquired a new stake in shares of AC Immune during the third quarter worth $134,000. Goldman Sachs Group Inc. acquired a new stake in shares of AC Immune during the second quarter worth $127,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of AC Immune during the third quarter worth $571,000. Institutional investors and hedge funds own 17.12% of the company’s stock.
WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/27/ac-immune-aciu-upgraded-by-bidaskclub-to-strong-buy.html.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.